JCO oncology practice最新文献

{"title":"Real-World Study of the Implementation of Early and Systematic Palliative Care for Advanced Colorectal Cancer Care-The Palliative Care Early and Systematic Project.","authors":"Jessica E Simon, Sharon M Watanabe, Patricia A Tang, Marc Kerba, Amy Tan, Madalene Earp, Camille Piquette, Janet Vandale, Patricia Biondo, Philip Akude, Aynharan Sinnarajah","doi":"10.1200/OP-25-00492","DOIUrl":"10.1200/OP-25-00492","url":null,"abstract":"<p><strong>Purpose: </strong>To develop and evaluate real-world interventions to move guidelines on timely palliative care utilization into practice.</p><p><strong>Methods: </strong>A knowledge-to-action cycle theory-informed, process improvement project facilitated implementation of a clinical practice guideline by (1) systematically screening clinic patients for unmet palliative care needs and alerting the oncologist, (2) using a dedicated community-based palliative care nurse for each referral, and (3) using Shared-care letters (structured communication between oncologist, family physician, and patient) to enhance information exchange and awareness of patients' needs. Implementation occurred for advanced colorectal cancer (CRC) within the GI clinics of the Tom Baker Cancer Center, Calgary, AB, Canada, and the neighboring city's Cross Cancer Institute, Edmonton, AB, Canada acted as control. The primary outcome was the proportion of adult decedents with CRC who received early specialist palliative care (SPC; defined as >90 days before death), evaluated using a pragmatic, controlled, before-and-after study. Eligible decedents in each city were identified using provincial cancer registry data and linked with administrative data identifying palliative care consultation, homecare, hospice, or inpatient unit usage.</p><p><strong>Results: </strong>The cohort included 695 decedents: 341 baseline period (153 control, 188 intervention, April 2017-December 2018) and 354 implementation period (145 control, 209 intervention, April 2019-December 2020); the mean age was 66.5 years, 60% was male, and 95.2% was urban-dwelling. In the intervention arm, the proportion of decedents who received palliative care >90 days before death increased from 44.7% at baseline to 57.4% after implementation; in the control arm, the proportion decreased from 47.7% to 44.1% (17.7% difference in differences [95% CI, 3.1-32.4]; <i>P</i> = .018).</p><p><strong>Conclusion: </strong>This intervention effectively increased early SPC utilization and provides a pragmatic approach to achieve and measure system-level change.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1719-1729"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145742631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Return to Intended Oncologic Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Discharged to a Skilled Nursing Facility.","authors":"Anirudh Yalamanchali, Preeyal Patel, Ali Mushtaq, Renato Samala, Nathan A Pennell","doi":"10.1200/OP-25-00429","DOIUrl":"10.1200/OP-25-00429","url":null,"abstract":"<p><strong>Purpose: </strong>Hospitalized patients with metastatic non-small cell lung cancer (mNSCLC) and poor performance status are commonly discharged to a skilled nursing facility (SNF) to undergo rehabilitation, with a plan for further systemic therapy as an outpatient. The success rate of this strategy is unknown.</p><p><strong>Patients and methods: </strong>Patients with mNSCLC between 2016 and 2023 discharged to a SNF were retrospectively reviewed, to find the proportion of patients who received further systemic therapy, quantify disease response, and characterize end-of-life care. Multivariable logistic regression was used to identify characteristics associated with receiving further therapy. Kaplan-Meier method was used to estimate overall survival (OS).</p><p><strong>Results: </strong>Of 427 patients, 131 (30.7%) received further therapy, with 40/54 (74.1%) of those planned for a tyrosine kinase inhibitor, 42/130 (32.3%) of those planned for an immune checkpoint inhibitor, and 49/243 (20.2%) of those planned for chemotherapy (<i>P</i> < .001). On multivariable analysis, the planned therapy type (<i>P</i> < .001) and 6-Clicks score (<i>P</i> < .001) were significantly associated with receiving further therapy. For those 131 patients, 51 (38.9%) died or enrolled in hospice without response assessment, 33 (25.2%) had progression at first assessment, and 48 (35.8%) had stable disease or a partial response. Systemic treatment was given in the last 30 days of life for 44 (33.6%) patients. Median OS was 1.7 months. Of the 410 patients who died, 97 (23.7%) died inpatient and 110 (26.8%) died at a facility without ever returning home.</p><p><strong>Conclusion: </strong>The number of patients who return to intended oncologic therapy is low, varying by therapy type and performance status. Few have subsequent disease response or stability, with many patients receiving therapy in the last 30 days of life or dying in the hospital.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1826-1836"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145563119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten Practical Rules for Outpatient Hematology Electronic Consults.","authors":"Alice Cusick, Veena Fauble, Irina Dobrosotskaya, Jason C Chen, Erin M Kropp, Scott D Gitlin","doi":"10.1200/OP-25-00716","DOIUrl":"10.1200/OP-25-00716","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1695-1700"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.","authors":"Claudia Marchetti, Gwenael Ferron, Olivier Colomban, Diana Giannarelli, Felix Blanc-Durand, Giovanni Scambia, Pierre-Alexandre Just, Domenica Lorusso, Eric Pujade-Lauraine, Raffaella Ergasti, Alain Lortholary, Carolina Maria Sassu, Isabelle Ray-Coquard, Filippo Maria Capomacchia, Pierre Combe, Adriana Ionelia Apostol, Gian Franco Zannoni, Aurore Carrot, Umberto Malapelle, Alexandra Leary, Anna Fagotti, Benoit You","doi":"10.1200/OP-25-00469","DOIUrl":"10.1200/OP-25-00469","url":null,"abstract":"<p><strong>Purpose: </strong>In patients with ovarian cancer undergoing neoadjuvant chemotherapy (NACT) with the goal of achieving complete interval cytoreductive surgery (ICS), tools are needed to accurately assess NACT efficacy and predict the feasibility of complete ICS after 3-4 cycles. The GINECO group (France) and Gemelli Hospital (Italy) analyzed two independent data sets to evaluate the predictive values of three tools available in routine.</p><p><strong>Methods: </strong>Data from CHIVA randomized phase II trial (ClinicalTrials.gov identifier: NCT01583322) and Policlinico Gemelli real-world registry (ID5936-ProtN45) were used to construct the French (N = 185) and Italian data sets (N = 357). Logistic regression models were used to identify the significant predictors-among modeled CA-125 Elimination Rate Constant K (KELIM); radiologic response; and <i>BRCA</i>/homologous recombination deficiency (HRD) status-of the following key indicators of successful ICS after NACT: (1) a low peritoneal carcinomatosis burden (Peritoneal Carcinomatosis Index [PCI]/Predictive Index Value [PIV]); (2) a complete CC0-R0 ICS); and (3) a pathologic Chemotherapy Response Score of 3 (CRS3).</p><p><strong>Results: </strong>In both French and Italian data sets, a favorable KELIM score ≥1.0 was reproducibly a predictor of higher probability of low PCI/PIV (odds ratios [OR], 2.92-4.19); CC0-R0 ICS (OR, 3.66-4.24); and pathologic CRS3 (OR, 2.36-21.44). An objective radiologic response was inconsistently associated with a lower PCI/PIV (OR, 1.78-3.69) and a CC0-R0 ICS (OR, 1.78-5.20). The <i>BRCA</i>/HRD status was not predictive of NACT efficacy. The proportion of patients achieving a CRS3 response was similar regardless of <i>BRCA</i>/HRD status.</p><p><strong>Conclusion: </strong>In two data sets, the tumor chemosensitivity assessed by the KELIM (online calculator)²⁹ was a consistent significant predictor of three critical outcomes associated with successful ICS after NACT. The radiologic response was inconsistently associated with lower disease bulk. The <i>BRCA</i>/HRD status was not predictive of NACT efficacy. These outcomes may inform decisions and future chemosensitizing innovative strategies.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1745-1755"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145596546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Is the Cost Impact of Second Opinions in Oncology? A Retrospective Review.","authors":"Benjamin R Roman, Allison Lipitz-Snyderman, Susan Chimonas, Brendan Raftery, Cole Manship, Arushi Mahajan, Leonard Saltz, Aaron Mitchell, David Miller, Smita Sihag, Daniel Gomez, Bobby Daly, Lauren Klein Levine","doi":"10.1200/OP-25-00586","DOIUrl":"10.1200/OP-25-00586","url":null,"abstract":"<p><strong>Purpose: </strong>Second opinions in oncology may optimize treatment plans, resulting in improved outcomes such as prognosis and morbidity. Changes in treatment plans are often de-escalations in treatment intensity. However, data on the cost impact of changes in cancer treatment resulting from second opinions are limited.</p><p><strong>Methods: </strong>We used a cohort of 120 patients who presented to a high-volume cancer center for a second opinion and also had a documented first opinion-30 patients each from four disease types: colorectal, head and neck, lung, and myeloma. For the 43 total patients who had a change in treatment from the second opinion compared with the first opinion, we estimated costs of treatment for the first and second opinions across the modalities of surgery, radiation, and drug treatment.</p><p><strong>Results: </strong>Among the 43 patients with a change between the first and second opinions, seven patients had a higher cost from the second opinion, 31 had a lower cost, and five had the same cost. Averaged across all 120 cases-43 with changes in treatment and the rest without-mean cost savings were $15,015 in US dollars (USD) per patient, ranging by disease type from $2,517 USD (lung) to $43,437 USD (myeloma). Decreases in cost were due to less-intensive surgery or drug therapy regimens, or shifts from treatment to no treatment (observation).</p><p><strong>Conclusion: </strong>Further investigation is needed across cancer types and in other settings to confirm the finding of de-escalations and resulting cost savings from second opinions.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1872-1879"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145661011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidermal Growth Factor Receptor Inhibitor Rechallenge: A Worthy Option in the Crowded Refractory Advanced Colorectal Cancer Space.","authors":"Suneel D Kamath","doi":"10.1200/OP-26-00151","DOIUrl":"10.1200/OP-26-00151","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1685-1688"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Program Evaluation of Acupuncture and Massage Services Delivered for Symptom Management at a Community Cancer Clinic.","authors":"Allison G Booher, Charles Rico, Rosa Nouvini, Kathleen Killoran, Pamela Drullinsky, Shaun Maxwell, Susan Li, Devika Jutagir, Kelly McConnell, Henry Godfrey, Malik Cadwell, Camila Casaw, William E Rosa, Rosario Costas Muñiz, Kevin T Liou","doi":"10.1200/OP-25-00321","DOIUrl":"10.1200/OP-25-00321","url":null,"abstract":"<p><strong>Purpose: </strong>High symptom burden disproportionately affects minoritized racial and ethnic groups during cancer treatments and exacerbates health disparities related to quality of life, treatment adherence, and overall survival. Acupuncture and massage have a growing evidence base for cancer symptom management, as shown in recent guidelines from ASCO and the Society for Integrative Oncology. However, access remains limited in community-based, underserved settings.</p><p><strong>Methods: </strong>We conducted a program evaluation of integrative medicine services at a community cancer clinic in East Harlem, New York. Auricular acupuncture and massage were offered 1 day a week to patients with cancer in the chemoinfusion suites at no additional cost. We collected demographics and clinical characteristics of patient visits, as well as types of treatments delivered and reasons treatments were not received. We assessed pain, fatigue, anxiety, and nausea immediately pre- and post-treatment, as well as patient satisfaction.</p><p><strong>Results: </strong>From 2022 to 2024, we offered acupuncture or massage at 635 patient visits, which were predominantly non-White (82.4%), Hispanic (44.9%), Spanish-speaking (31.7%), and Medicaid-insured (45.5%). Of these 635 patient visits, 396 (62.4%) received acupuncture or massage. Of the 239 who did not receive treatment, the most common reasons were lack of time (54.4%) and lack of interest (38.9%). Rates of treatment receipt were higher among female, Hispanic, Spanish-speaking, Medicare-insured, and chemotherapy patient visits (all <i>P</i> < .05). Patients reported reductions in pain, fatigue, anxiety, and nausea immediately post-treatment. More than 90% of treatment recipients reported satisfaction with the program.</p><p><strong>Conclusion: </strong>This program reached a diverse, underserved population with historically limited access to integrative therapies. The findings highlight the barriers and facilitators to bringing acupuncture and massage services to community-based oncology settings.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1730-1738"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12695011/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145677626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Systems Theory Model to Understand the Barriers and Facilitators to Palliative Care Referral for Pediatric Oncology Patients in Canada.","authors":"Leeat Granek, Fyeza Hasan, Dave Lysecki, Donna Johnston, Stephanie Veldhuijzen van Zanten, Nathasha Datoo, Sumit Gupta, Anthony Chan, Lori Wiener, Kimberley Widger, Emily McCullogh, Alisha Kassam, Karen Fergus, Adam Rapoport","doi":"10.1200/OP-26-00781","DOIUrl":"10.1200/OP-26-00781","url":null,"abstract":"","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"e7"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148421156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rechallenge With an Epidermal Growth Factor Receptor Inhibitor in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.","authors":"Amy H Huang, Gin Yi Lee, Chuan Angel Lu, Ibrahim Halil Sahin, Gentry T King, Rachael A Safyan, Stacey A Cohen, David B Zhen, Veena Shankaran, William P Harris, Andrew L Coveler, Jyoti Malhotra, Victoria E Forbes, Philip J Gold, E Gabriela Chiorean, Ronan W Hsieh","doi":"10.1200/OP-25-00646","DOIUrl":"10.1200/OP-25-00646","url":null,"abstract":"<p><strong>Purpose: </strong>Clonal evolution is a mechanism of treatment resistance against epidermal growth factor receptor inhibitors (EGFRi) in metastatic colorectal cancer (mCRC). When EGFRi is discontinued, EGFRi-resistant tumor subclones decay with time, allowing for EGFRi rechallenge at later time. We conducted a meta-analysis to investigate the efficacy of EGFRi rechallenge in mCRC.</p><p><strong>Methods: </strong>Clinical trials and observational studies investigating the efficacy of EGFRi rechallenge in mCRC were included from PubMed and Embase from inception to December 8, 2024. Hazard ratios (HRs) of overall survival (OS) and progression-free survival (PFS) were aggregated using Bayesian random-effects models. Objective response rates (ORRs) were aggregated using meta-random-effects models.</p><p><strong>Results: </strong>Twenty-nine studies were included. The pooled median PFS, median OS, and ORR were 3.83 months (95% CI, 3.25 to 4.50), 10.43 months (95% CI, 8.14 to 13.36), and 14.61% (95% CI, 8.70 to 23.51), respectively. EGFRi rechallenge was associated with significantly longer pooled PFS (HR, 0.54 [95% CI, 0.31 to 0.93]) and numerically longer pooled OS (HR, 0.71 [95% CI, 0.46 to 1.09]) than non-EGFRi systemic therapy. Patients without detectable RAS/RAF mutations by circulating tumor DNA (ctDNA) at the time of EGFRi rechallenge had significantly longer OS (HR, 0.43 [95% CI, 0.24 to 0.75]) and PFS (HR, 0.40 [95% CI, 0.26 to 0.62]) than those with ctDNA RAS/RAF mutations. Studies with EGFRi-free intervals ≥4 months before rechallenge (18.77%) had a numerically greater pooled ORR than those with EGFRi-free intervals <4 months (6.60%). No unexpected adverse events were reported, and treatment discontinuation because of adverse events was 2.7%.</p><p><strong>Conclusion: </strong>EGFRi rechallenge is associated with significantly longer PFS, numerically longer OS, and clinically meaningful ORR as compared with non-EGFRi systemic therapy in mCRC, particularly for ctDNA RAS/RAF wild-type mCRC.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"1701-1712"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Comparative Effectiveness of Abiraterone, Apalutamide, Enzalutamide, and Docetaxel Doublets for Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Ifechukwu B Nwogu, Noemi Kreif, Hiba M Khan, Ruth Etzioni, Josh J Carlson","doi":"10.1200/OP-26-00493","DOIUrl":"https://doi.org/10.1200/OP-26-00493","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the real-world comparative effectiveness of androgen receptor pathway inhibitors (ARPIs)-abiraterone, apalutamide, enzalutamide-and docetaxel, plus androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC).</p><p><strong>Methods: </strong>We identified US men with mHSPC who initiated ADT within 4 months of diagnosis and were treated with abiraterone, apalutamide, enzalutamide, or docetaxel within 4 months of ADT initiation between January 2019 and December 2023, with follow-up through June 2025. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included time to metastatic castration-resistant prostate cancer (mCRPC) progression (TTP) and time to new treatment initiation (TTNT). Cox proportional hazard and Fine-Gray models with overlapping propensity score weights were used to estimate primary and secondary outcomes, respectively. Subgroup analyses by timing of metastasis and sensitivity analyses using inverse probability of treatment weights were conducted for primary outcomes.</p><p><strong>Results: </strong>Among 9,141 US men with mHSPC, ARPI doublets demonstrated superior PFS versus docetaxel doublets (abiraterone: adjusted hazard ratio [aHR], 0.60 [95% CI, 0.55 to 0.66]; apalutamide: aHR, 0.64 [95% CI, 0.56 to 0.73]; enzalutamide: aHR, 0.57 [95% CI, 0.51 to 0.64]), with no significant differences among ARPI regimens. OS was comparable among all doublet regimens. Neither PFS nor OS differed by timing of disease. TTP (abiraterone: aHR, 0.52 [95% CI, 0.47 to 0.58]; apalutamide: aHR, 0.59 [95% CI, 0.52 to 0.68]; enzalutamide: aHR, 0.51 [95% CI, 0.45 to 0.57]) and TTNT (abiraterone: aHR, 0.46 [95% CI, 0.42 to 0.51]; apalutamide: aHR, 0.53 [95% CI, 0.46 to 0.61]; enzalutamide: aHR, 0.47 [95% CI, 0.42 to 0.53]) showed similar patterns favoring ARPI doublets. Sensitivity analyses showed consistent findings.</p><p><strong>Conclusion: </strong>ARPI doublets demonstrated superior PFS but similar OS compared with docetaxel doublet, with no differences among individual ARPIs. Patients receiving ARPI doublets were less likely to progress to mCRPC or initiate new treatment.</p>","PeriodicalId":14612,"journal":{"name":"JCO oncology practice","volume":" ","pages":"OP2600493"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149109584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}